Submitted for Publication: December 9, 2011; final revision received March 15, 2012; accepted April 25, 2012.
Published Online: July 2, 2012.doi:10.1001/archgenpsychiatry.2012.650
Author Contributions: Dr Birmaher takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors had full access to all the data in the study.
Conflict of Interest Disclosures: Dr T. R. Goldstein received research support from the NIMH, the National Institute on Drug Abuse, the Pittsburgh Foundation, and the Ryan Licht Sang Bipolar Foundation and royalties for publication from Guilford Press. Drs Axelson, Ryan, Yen, Hunt, and Strober received research support from the NIMH. Dr B. I. Goldstein received research support from Pfizer, was an unpaid consultant for Bristol-Myers Squibb, and received speaker's honoraria from Purdue Pharma. Dr Keller received research support from the NIMH and Eli Lilly and consulted and served on the speaker's bureaus or advisory boards for Abbott, Cenerex, Cephalon, Cyberonics, Cypress Bioscience, Forest, Janssen, JDS, Medtronic, Neuronetics, Novartis, Organon, Pfizer, Roche, Sierra Pharmaceuticals, Shire, Solvay, and Wyeth Ayerst. Dr Birmaher received research support from the NIMH and has or will receive royalties for publications from Random House and Lippincott Williams & Wilkins.
Funding/Support: This study was supported by grants MH59929 (Dr Birmaher), MH59977 (Dr Strober), MH59691 (Dr Keller), and MH074581 (Dr T. R. Goldstein) from the NIMH.
Additional Contributions: We thank the following COBY raters: Jennifer Fretwell, BA; Kerry Gagnon, BA; Matt Killam, BA; Eunice Kim, PhD; Norman Kim, PhD; Sharon Nau, MS; Marguerite Shashoua, BA; and Jessica Wrona, BS. We thank the data personnel Katherine Aronson, BA, and Metanthi Tzanakos, BS. We thank Satish Iyengar, PhD, for statistical consultation. We thank Shelli Avenevoli, PhD, at the NIMH for her support and guidance.